Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer.

OBJECTIVE To elucidate the clinical significance of the methylated status of CpG sites of dapper homolog 1 (DACT1) promoter in the survival prediction in gastric cancer (GC). METHODS The large scale GC patients (n=459) were analyzed for the quantitatively methylated status of CpG sites of DACT1 DNA promoter with the bisulphite sequencing PCR (BSP). With gene sequencing analysis, the methylated statuses of 12 cytosine-phosphate-guanine (CpG) sites in DACT1 promoter were detected to supply detailed information for the precisely prognostic prediction. Associations between molecular, clinicopathologic, and survival data were analyzed. RESULTS With the MSP detection, different methylated levels of DACT1 promoter were identified in the 25 GC tissues, while none of 25 normal gastric mucosal tissues were found to be methylated. DACT1 promoter methylation was found in 28.32% in 459 patients. GC patients with 4 or more methylated CpG sites of DACT1 promoter was significantly associated with the poorer survival (P=0.19). The methylated statuses of CpG -515, CpG -435, and CpG -430 sites were also identified to provide the elaborate survival discrimination for 459 GC patients, respectively (P=0.049, =0.006, and =0.037). In addition, we demonstrated that the methylated CpG site count had smallest AIC and BIC values than other three methylated status of CpG sites for prediction the survival of 459 GC patients. CONCLUSIONS The methylated CpG site count of DACT1 promoter had the significant applicability for clinical evaluation the prognosis of GC.

[1]  R. Langer,et al.  Prediction of Prognosis Is Not Improved by the Seventh and Latest Edition of the TNM Classification for Colorectal Cancer in a Single-Center Collective , 2011, Annals of surgery.

[2]  Fumiaki Sato,et al.  CpG island hypermethylation in progression of esophageal and gastric cancer , 2006, Cancer.

[3]  Yue Zhao,et al.  Downregulation of HDPR1 is associated with poor prognosis and affects expression levels of p120‐catenin and β‐catenin in nonsmall cell lung cancer , 2010, Molecular carcinogenesis.

[4]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[5]  Nayoung Kim,et al.  Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection , 2009, The Journal of pathology.

[6]  S. Fan,et al.  HDPR1, a novel inhibitor of the WNT/β-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing , 2005, Oncogene.

[7]  Jun Yu,et al.  Concurrent hypermethylation of multiple tumor‐related genes in gastric carcinoma and adjacent normal tissues , 2001, Cancer.

[8]  Satoshi Yamashita,et al.  Estimation of the Fraction of Cancer Cells in a Tumor DNA Sample Using DNA Methylation , 2013, PloS one.

[9]  Zengjun Wang,et al.  The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma , 2011, Journal of biomedical research.

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  M. Katoh,et al.  Identification and characterization of human DAPPER1 and DAPPER2 genes in silico. , 2003, International journal of oncology.

[12]  Bin Xie,et al.  Long-Lasting Changes in DNA Methylation Following Short-Term Hypoxic Exposure in Primary Hippocampal Neuronal Cultures , 2013, PloS one.

[13]  Tianyuan Wang,et al.  A Minimal Set of Tissue-Specific Hypomethylated CpGs Constitute Epigenetic Signatures of Developmental Programming , 2013, PloS one.

[14]  L. Shen,et al.  Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. , 2011, Hepato-gastroenterology.

[15]  Jun-qi Wang,et al.  Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[16]  H. Wilke,et al.  Treatment strategies in gastric cancer. , 2011, Deutsches Arzteblatt international.

[17]  Shengnan Jin,et al.  Improved reduced representation bisulfite sequencing for epigenomic profiling of clinical samples , 2013, Biological Procedures Online.

[18]  Yun Ku Cho,et al.  Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization , 2008, Cancer.

[19]  R. Nusse,et al.  Wnt signaling in disease and in development , 2005, Cell Research.

[20]  Jun Yu,et al.  Dapper Homolog 1 Is a Novel Tumor Suppressor in Gastric Cancer through Inhibiting the Nuclear Factor-κB Signaling Pathway , 2012, Molecular medicine.

[21]  David D. Smith,et al.  Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Q. Tao,et al.  DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer , 2013, Breast Cancer Research.